Endovascular Cardiac Valve Replacement DRG Reimbursement Guide

DRG 267 includes endovascular cardiac valve replacement and supplemental procedures without Major Complication or Comorbidity, representing transcatheter valve interventions coded without significant additional complications. This Diagnosis-Related Group is important for inpatient reimbursement because it defines the bundled payment for these procedures under Medicare prospective payment systems and influences hospital revenue for endovascular valve cases.

DRG 267 Overview

DRG 267 covers hospital admissions for endovascular cardiac valve replacement and supplemental procedures without Major Complication or Comorbidity. This Diagnosis-Related Group encompasses transcatheter aortic valve replacement and related percutaneous valve procedures performed without significant additional complications. It matters for Medicare payment because it groups resource use for reimbursement and determines inpatient prospective payment classification. Accurate coding and documentation affect case assignment to this Diagnosis-Related Group and consequent payment levels.

DRG 267 Overview

Acute procedural optimization trials focusing on periprocedural antithrombotic strategies and immediate hemodynamic management for patients undergoing endovascular cardiac valve replacement (transcatheter aortic or mitral valve procedures) without major complications. These studies enroll predominantly older adults with symptomatic valvular disease undergoing valve-in-valve or native valve transcatheter replacement and evaluate timing, dosing, and combinations of antiplatelet and anticoagulant therapy, as well as rapid heart rate and blood pressure control protocols during and immediately after the procedure. Findings inform clinicians about balancing bleeding versus thrombotic risk in the acute inpatient setting and help payers assess short-term complication rates and resource use tied to different periprocedural care pathways.
Comparative effectiveness and device-performance studies that compare implant techniques, valve platforms, and adjunctive imaging strategies in intermediate- to high-surgical-risk patients who receive endovascular valve replacement without major complications. These trials examine clinical outcomes such as paravalvular leak, need for pacemaker implantation, procedure duration, and short-term readmission rates across different procedural approaches and imaging guidance protocols. Results guide hospital procurement and procedural protocols, influencing reimbursement decisions by demonstrating which approaches yield better early outcomes and lower downstream utilization for this DRG cohort.
Post-discharge longitudinal outcomes and care-coordination studies assessing recovery trajectories, functional status, and healthcare utilization in patients after uncomplicated endovascular valve replacement. These observational or pragmatic randomized studies follow patients through the first 30–90 days and beyond to measure readmissions, rehabilitation needs, medication adherence, and quality-of-life metrics, often stratified by baseline frailty and comorbidity burden. Evidence from these studies is critical for providers and payers to design efficient discharge planning, home-health strategies, and bundled-payment models that reduce avoidable readmissions and optimize value for patients in this DRG.

Acute procedural optimization trials focusing on periprocedural antithrombotic strategies and immediate hemodynamic management for patients undergoing endovascular cardiac valve replacement (transcatheter aortic or mitral valve procedures) without major complications. These studies enroll predominantly older adults with symptomatic valvular disease undergoing valve-in-valve or native valve transcatheter replacement and evaluate timing, dosing, and combinations of antiplatelet and anticoagulant therapy, as well as rapid heart rate and blood pressure control protocols during and immediately after the procedure. Findings inform clinicians about balancing bleeding versus thrombotic risk in the acute inpatient setting and help payers assess short-term complication rates and resource use tied to different periprocedural care pathways.
Comparative effectiveness and device-performance studies that compare implant techniques, valve platforms, and adjunctive imaging strategies in intermediate- to high-surgical-risk patients who receive endovascular valve replacement without major complications. These trials examine clinical outcomes such as paravalvular leak, need for pacemaker implantation, procedure duration, and short-term readmission rates across different procedural approaches and imaging guidance protocols. Results guide hospital procurement and procedural protocols, influencing reimbursement decisions by demonstrating which approaches yield better early outcomes and lower downstream utilization for this DRG cohort.
Post-discharge longitudinal outcomes and care-coordination studies assessing recovery trajectories, functional status, and healthcare utilization in patients after uncomplicated endovascular valve replacement. These observational or pragmatic randomized studies follow patients through the first 30–90 days and beyond to measure readmissions, rehabilitation needs, medication adherence, and quality-of-life metrics, often stratified by baseline frailty and comorbidity burden. Evidence from these studies is critical for providers and payers to design efficient discharge planning, home-health strategies, and bundled-payment models that reduce avoidable readmissions and optimize value for patients in this DRG.

OpenPayer

Endovascular Cardiac Valve Replacement: Inpatient Reimbursement Overview

Sign up for drg 267 policy alerts

DRG 267 Overview

OpenPayer

Endovascular Cardiac Valve Replacement: Inpatient Reimbursement Overview

Sign up for drg 267 policy alerts

DRG 267 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References